Recent Updates
Recently added Catalysts
TLPH Positive Sentiment

Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Tuesday, October 8, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Talphera, Inc. will participate in the 2024 Maxim Healthcare Virtual Summit, scheduled for October 15-17, 2024. During the summit, management will engage in a fireside chat and hold one-on-one meetings with registered investors. The event reflects Talphera's ongoing commitment to transparency and investor relations. The company is recognized for its innovative therapies, particularly its lead product candidate Niyad™, which has received FDA Breakthrough Device Designation as an anticoagulant.
Price reaction · baseline $0.79 (2024-10-07 close) · hit after-hours · clean, no other TLPH news in the window
day 0 close
+0.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Talphera will participate in a significant industry event, promoting visibility.
  • Management engagement with investors at the summit suggests confidence in their strategy.
  • The company has received FDA Breakthrough Device Designation for its lead product.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+222%
120-day peak, hindsight
Typical move
22.4%
average across 2 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
sufentanil
Phase 3 · Moderate-to-severe Acute Pain

Full Press Release Details

SAN MATEO, Calif., Oct. 8, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit and will be available for 1x1 meetings with registered investors. The summit is being held on October 15-17, 2024.
Event: 2024 Maxim Healthcare Virtual Summit
Date: October 16, 2024
Time: 3:00 PM ET / 12:00 Noon PT
Webcast link: 2024 Maxim Healthcare Virtual Summit
About Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).
This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.

Frequently Asked Questions

When is the 2024 Maxim Healthcare Virtual Summit?

The summit will be held from October 15-17, 2024.

What is Talphera's lead product candidate?

Talphera's lead product candidate is Niyad™, a nafamostat formulation.

What designation has Niyad™ received from the FDA?

Niyad™ has been granted Breakthrough Device Designation by the FDA.

What time is Talphera's presentation at the summit?

Talphera's presentation is scheduled for October 16, 2024, at 3:00 PM ET.

Where can I find more information about Talphera?

Additional information can be found on Talphera's website at www.talphera.com.

ShareAdd on Google
Tags: TLPH Viatris Investor Conferences Healthcare Talphera Niyad 155 chars Maxim Healthcare
Last updated: Oct 8, 2024

Biotech snapshot

Cash runway
$17M liquidity · $1M/mo burn
~13 mo
Low dilution risk
Lead asset
sufentanilPhase 3
Moderate-to-severe Acute Pain →

Catalyst track record

+222%
best trade around TLPH's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for TLPH.

See every catalyst's timing & PoA →